Bellerophon Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ market, and it sits squarely within the Health & Pharma sector. Headquartered in Warren, New Jersey, United States, the company has built its identity around the development of innovative respiratory therapies, with a long-standing focus on pulmonary disease and pulmonary hypertension. Its business model is that of a clinical-stage biotech: value creation depends primarily on research execution, clinical validation, regulatory progress, and intellectual property protection rather than on an established commercial drug portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1600132/000155837023005200/blph-20221231x10k.htm?utm_source=openai)) The company’s core asset has historically been INOpulse®, a nitric oxide inhalation delivery platform designed to target selected chronic lung conditions. Bellerophon has explored applications in fibrotic interstitial lung disease, COPD associated with pulmonary hypertension, pulmonary sarcoidosis, and, at one point, COVID-19-related programs. That narrow pipeline makes Bellerophon a highly specialized platform company: successful clinical readouts could be transformational, but the shares are also highly exposed to trial outcomes, regulatory decisions, and capital-market conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1600132/000155837023005200/blph-20221231x10k.htm?utm_source=openai)) From a historical standpoint, Bellerophon emerged in 2014 and has remained a New Jersey-based biotech with a footprint in Warren, a location that keeps it close to the broader U.S. East Coast life-sciences corridor. SEC filings show principal offices and research space in Warren, reinforcing the picture of a small, development-stage company rather than a commercial pharmaceutical group. For investors, this matters: the company’s operating profile is defined by lean infrastructure, a concentrated R&D strategy, and the need to preserve flexibility while advancing one or a few clinical programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1600132/000160013220000039/blph-12312019x10k.htm?utm_source=openai)) In competitive terms, Bellerophon is positioned in a niche area of respiratory medicine built around targeted nitric oxide delivery. Its differentiation is not broad product breadth, but rather the potential utility of its delivery technology and the clinical logic supporting chronic pulmonary indications. That can create meaningful upside if clinical data translate into a favorable benefit-risk profile, but it also leaves the company vulnerable to competition from alternative therapeutic approaches, standard-of-care treatments, and the practical challenges of drug-device development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1600132/000155837023005200/blph-20221231x10k.htm?utm_source=openai)) Recent developments highlight the company’s high-risk, high-uncertainty profile. In 2023 and 2024, Bellerophon communicated the results of the REBUILD Phase 3 study of INOpulse in fibrotic interstitial lung disease and disclosed corporate actions linked to its capital structure and listing situation. SEC filings and related disclosures point to liquidity pressure and going-concern concerns, which are common—but still material—signals for a micro-cap clinical biotech. For French, Belgian, and Swiss investors, Bellerophon should therefore be viewed as a highly speculative NASDAQ-listed U.S. biotech whose investment case hinges on clinical data, regulatory milestones, and its ability to finance ongoing development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1600132/000110465923067854/tm2317784d1_ex99-1.htm?utm_source=openai))